A vaccine can help prevent dengue, which is caused by four distinct, but closely related dengue viruses, DENV-1, DENV-2, DENV-3, and DENV-4. Only one dengue vaccine is currently available for use:
- A tetravalent, live-attenuated dengue vaccine (Dengvaxia®)
Dengvaxia will be available starting in 2022 for use in children 9 through 16 years old who have laboratory-confirmed previous dengue virus infection and are living in an area where dengue is endemic (occurs frequently or continuously). Dengue-endemic areas include the U.S. territories of American Samoa, Puerto Rico, and the U.S. Virgin Islands, and freely associated states, including the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau.
Talk to your child’s healthcare provider if you have questions about the dengue vaccine.